Another study combining 110 BRAF-mutated and 798 wild-type colon cancer patients from TCGA datasets (59 BRAF-mutated, 337 BRAF wild-type) and GEO datasets (51 BRAF-mutated, 441 BRAF wild-type) found that M1 macrophages (P < 0.001, in both datasets) were higher in BRAF mutated patients than that in wild-type patients, and no significant differences of M2 macrophages between BRAF mutant patients and BRAF wild-type patients (P > 0.05, in both datasets) [85]. This evidence concerns the gene BRAF and malignant colon neoplasm.